EMA Authorised: Arikayce liposomal (amikacin sulfate) — Insmed Netherlands B.V.

View source ↗

Summary

EMA authorised Arikayce liposomal (amikacin sulfate) for respiratory tract infections, granted orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Tract Infection

Drugs mentioned

• Arikayce liposomal (amikacin sulfate)

Snippet

Status: Authorised. Therapeutic area: Respiratory Tract Infections. MAH: Insmed Netherlands B.V.. Decision date: 15/07/2026. Orphan medicine